- Home
- AORT vs XERS Comparison
AORT vs XERS Comparison
Compare AORT & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AORT | XERS |
|---|---|---|
| Founded | 1984 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.6B |
| IPO Year | 1996 | 2021 |
Fundamental Metrics
Financial Performance| Metric | AORT | XERS |
|---|---|---|
| Price | $26.88 | $8.46 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $49.40 | $10.83 |
| AVG Volume (30 Days) | 719.0K | ★ 1.6M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 165.62 | 100.00 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $298,836,000.00 | $49,590,000.00 |
| Revenue This Year | $14.20 | $34.37 |
| Revenue Next Year | $11.20 | $22.86 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 18.01 | ★ 142.67 |
| 52 Week Low | $19.16 | $5.25 |
| 52 Week High | $48.25 | $10.08 |
Technical Indicators
Market Signals| Indicator | AORT | XERS |
|---|---|---|
| Relative Strength Index (RSI) | 49.27 | 51.61 |
| Support Level | $25.79 | $8.00 |
| Resistance Level | $28.29 | $9.01 |
| Average True Range (ATR) | 1.15 | 0.32 |
| MACD | -0.31 | -0.01 |
| Stochastic Oscillator | 20.02 | 49.22 |
Price Performance
Historical ComparisonAbout AORT Artivion Inc.
Artivion Inc offers cardiac and vascular surgeons a suite of aortic-centric solutions. The company's products include Aortic Heart Valve, Mitral Heart Valve, Aortic Allograft, Pulmonary Human Heart Valve, Pulmonary Patch, and Surgical Adhesive among others. The company's has two reportable segments: Medical Devices and Preservation Services. The Medical Devices segment includes revenues from sales of aortic stent grafts, surgical sealants, On-X products, and other product revenues. The Preservation Services segment includes services revenues from the preservation of cardiac and vascular implantable human tissues. Company operates in North America, EMEA. LATAM, APAC. Maximum revenue is from North America.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.